Catalent Biologics Content

  1. Catalent Capabilities Update June 2026: Cell Line Development 6/24/2026

    Discover how an integrated approach to transient expression, cell line development, and manufacturing can accelerate biologics development from gene to IND.

  2. Structuring ADC Analytical Partnerships From Pre-IND To Commercial 6/17/2026

    ADC success depends less on molecular design than on a continuous analytical strategy that connects early characterization to late-stage control, preventing variability, data gaps, and regulatory issues from compounding over time.

  3. Accelerating Antibody Development: A Proven Path From Gene To GMP 6/5/2026

    Discover how an optimized, end-to-end development strategy can help sponsors reach key clinical milestones faster and bring potentially life-saving therapies to patients sooner.

  4. GPEx® Lightning: Stable Cell Line Development For Complex Biologics 6/5/2026

    GPEx® Lightning delivers stable cell pools in 25 days, titers exceeding 15g/L for mAbs and 11g/L for bispecifics, and 60+ generations of stability — compressing timelines by 6–12 weeks.

  5. Madison: Clinical, Commercial Drug Substance Development 6/2/2026

    Catalent Madison offers gene-to-GMP drug substance in 8 months via GPEx Lightning CHO cell lines, hitting 15+ g/L, backed by 24 approved products and 5 GMP trains up to 4,000 L.

  6. Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development 5/8/2026

    Cut HEK cell line development to four months with 30% higher titers. GPEx® Lightning delivers faster, scalable biologics manufacturing. Access the full summary now.

  7. The Growing Strategic Importance Of CDMOs In CGT 5/8/2026

    Discover how advanced manufacturing platforms, integrated analytics, and accelerated development strategies are helping overcome the scalability, supply chain, and operational challenges.

  8. Streamlining Process Characterization Toward Successful Validation Campaigns 5/8/2026

    Compress your biologics process characterization timeline without sacrificing quality. Learn how FMEA, DoE, and platform approaches help you hit PPQ readiness faster while managing regulatory risk.

  9. A Systematic Approach To Assess Biologics Developability 5/8/2026

    Discover how a systematic, data-driven developability workflow can accelerate biologic formulation development, identify risks earlier, and optimize stability and manufacturability.

  10. Why Comprehensive Analytical Services Are Core To The Future Of Antibody-Drug Conjugates 5/5/2026

    ADCs require integrated, early-stage analytics to manage complex interactions among components, enabling better characterization, reduced development risk, and faster, more reliable progression from discovery through regulatory approval.